VACCINEX INC
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
VCNX$1.41-61.4%Stored close · as of Dec 17, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Operations and Comprehensive Loss (Unaudited)
(in thousands, except share and per share data)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Revenue | $104 | $550 |
| Costs and expenses: | ||
| Research and development | 3,383 | 3,812 |
| General and administrative | 1,795 | 1,724 |
| Total costs and expenses | 5,178 | 5,536 |
| Loss from operations | (5,074) | (4,986) |
| Financing costs - warrant liabilities | (28) | - |
| Change in fair value of warrant liabilities | 1,206 | - |
| Other income (expense), net | (1) | 24 |
| Loss before provision for income taxes | (3,897) | (4,962) |
| Provision for income taxes | - | - |
| Net loss attributable to Vaccinex, Inc. common stockholders | $(3,897) | $(4,962) |
| Comprehensive loss | $(3,897) | $(4,962) |
| Net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted | $(2.94) | $(20.89) |
| Weighted-average shares used in computing net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted | 1,327,257 | 237,527 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.